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Abstract Little is known about the effect of anemia
correction with erythropoietin (EPO) on B-type natriuretic
peptide (BNP) levels, NYHA class, and hospitalization
rate. The aim of the study was to investigate, in patients
with cardio-renal anemia syndrome, the effects of EPO on
hemochrome and renal function parameters and BNP lev-
els. We also analyzed the effect of EPO therapy on hos-
pitalization rate and NYHA class after 12 months in
comparison with a population undergoing to standard
therapy. We performed a randomized double-blind con-
trolled study of correction of the anemia with subcutaneous
a (group A n = 13) or b (group B n = 14) EPO for
12 months in addition to standard therapy with oral iron in
27 subjects. Control group (n = 25 patients) received only
oral iron. Significant increase in hemoglobin (Hb),
hematocrit (Hct), and red blood cells (RBC) were revealed
in EPO groups at 12 months; Hb, group A 12.3 ± 0.6;
group B 11.7 ± 0.8; control group 10.6 ± 0.5 g/dl
P \ 0.0001; Hct group A 34.2 ± 2.3, group B 34 ± 2,
control group 32.3 ± 1.8% P \ 0.01; RBC, group A
3.9 ± 0.2, group B 3.8 ± 0.2, control group 3.3 ± 0.2,
(P \ 0.0001). Plasma BNP levels in EPO groups were
significantly reduced after 12 months (group A: 335 ± 138
vs. group B: 449 ± 274 pg/ml control group 582 ±
209 pg/ml (P \ 0.01). After 12 months of treatment, hos-
pitalization rate and NYHA class were reduced in EPO
groups with respect to control group (P \ 0.05). Finally, an
inverse correlation was observed between BNP and Hb
levels in EPO Groups (r = -0.70 P \ 0.001). EPO treat-
ment reduces BNP levels and hospitalization rate in
patients with cardio-renal anemia syndrome. The correc-
tion of anemia by EPO treatment appears able to improve
clinical outcome in this subset of patients with heart
failure.
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Introduction
Anemia is a clinical manifestation commonly observed in
patients with congestive heart failure (CHF) and renal
disease [1–9]. Prevalence of this condition is estimated to
be between 15 and 55%, depending on the clinical defini-
tion of anemia. The prevalence of anemia has been found
to be greater in those with older age, more advanced New
York Heart Association (NYHA) classes, diabetes, more
severe systolic dysfunction, more reduced exercise toler-
ance, and more reduced renal function [1–9]. Anemia in
patients with CHF is often associated with a more adverse
outcome including increased mortality, morbidity, and
hospitalization [1–9]. It is known that anemia alone, even
without the presence of CHF, can increase heart rate and
cardiac output, and cause increased levels of renin,
angiotensin, aldosterone, antidiuretic hormone, sympa-
thetic activity and Natriuretic Peptides, reduce renal blood
flow, and glomerular filtration rate and increase plasma and
interstitial volume [10]. However, it is still not certain
whether the anemia in CHF is actually causing the increase
in adverse effects or is merely an innocent bystander, a
marker for other causes such as inflammation with
increased cytokines and/or renal failure [1–10].
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Erythropoietin (EPO) is a glycoprotein growth factor
produced by the kidney. In CHF, treatment with recombi-
nant human EPO increased the hemoglobin (Hb) concen-
tration and improved many aspects of CHF including
functional status and quality of life [11–20]. However,
most of interventional studies conducted in patients with
CHF and anemia that showed an improvement in exercise
tolerance and in functional status were uncontrolled studies
[11] or controlled studies but without a placebo [12–20]. In
the present study, we extend the previous studies by
investigating the effects of subcutaneous (sc) EPO and oral
iron versus oral iron alone on laboratory parameters, BNP
levels, and on clinical outcome (hospitalization rate and
NYHA classes) during one-year follow-up period.
Materials and methods
Patient population
The starting patients number consisted in 80 subjects with a
history of moderate to severe CHF (NYHA Class III or IV),
mild to moderate renal insufficiency with CrCl between 60
and 30 ml/min, and anemia (defined as Hb levels below
11.5 g/dl on two occasions separated by 1–2 weeks).
Before the enrollment, all patients underwent optimized
medical treatment for CHF, according to the last ESC
guidelines [21]. The study population was homogenous for
exercise tolerance, co-morbidities, laboratory investiga-
tions, and echocardiographic examination.
Exclusion criteria
Patients with isolated diastolic dysfunction, more than
moderate valvular disease, recent myocardial infarction
(within 12 weeks), modifiable causes of anemia, severe
renal failure, and gastrointestinal bleeding were excluded.
All patients undergoing fecal occult blood tests, if it was
positive, were also excluded.
Study protocol: double-blind period
Group A, consisting of 13 patients, was treated with sub-
cutaneous (sc) a—EPO twice weekly and daily oral iron as
a ferrous gluconate 300 mg tablet.
Group B, consisting of 14 patients, was treated with
subcutaneous (sc) b—EPO twice weekly and daily oral
iron as a ferrous gluconate 300 mg tablet. Control group
(25 patients) received the oral iron alone and sc saline
injections twice weekly.
The EPO and saline injections were similar and it was
impossible to know which syringes the patients received.
The physicians were unaware which syringes they used.
The dose of EPO was 6,000 international units (IU). The
EPO or placebo were done twice weekly for 12 months.
All patients referred to our ambulatories for standard
clinical checkups, as before the study, on the basis of their
clinical status. If any adverse effect or treatment was
manifested during follow-up, this was immediately inter-
rupted. Both groups were re-evaluated for the study at
12 months from onset of experimental protocol.
Laboratory analysis
A complete blood count with Hb, Hct, red blood cell
(RBC) count, RBC indices, serum creatinine sodium, and
potassium were performed at baseline and after 12 months
of treatment. Creatinine clearance was estimated from the
serum creatinine values using the Cockroft-Gault formula
[22]. Plasma BNP was measured at the beginning and at the
end of the study, using the quantitative immunofluores-
cence assay manufactured by Biosite (San Diego, CA,
USA). The analytic sensitivity of the assay is\5 pg/ml and
the upper normal limit is considered to be 100 pg/ml.
Primary and secondary end points
Primary end points assessed were laboratory data including
Hb, hematocrit (Hct), red blood cells (RBC), and creatinine
clearance; these parameters were evaluated at the start and
at the end of the 12-month study period. BNP modifications
were evaluated at the beginning and after 12 months. For
each patient, NYHA class was obtained at baseline and at
12 months of follow-up. Secondary end points that were
monitored included sudden death, hospitalizations, and
myocardial infarction.
Statistical analysis
Continuous data were expressed as mean ± SD. The data
were analyzed for statistically significant differences by
ANOVA/ANCOVA test for unpaired data and by linear
correlation using the SPSS 17 for Windows (SPSS Inc,
Chicago IL). The significant level was set at P \ 0.05.
Results were considered significant if there was, within or
between group analyses, a statistical confidence level of
95%.
Results
Of the 80 consecutively recruited patients, only 56 had
inclusion criteria. Of these, 2 refused to continue the study
protocol and 2 needed blood transfusions to correct their
anemia. Four patients died during the follow-up period (3
in control group and 1 in EPO groups). Thus, only 48
44 Clin Exp Med (2011) 11:43–48
123
patients completed the follow-up study. During the
12 months follow-up, no adverse effects due to the treat-
ment were reported. Thirty patients were in NYHA class III
and 22 were in class IV. General and clinical characteris-
tics of the study population are summarized in Table 1.
Significant increase in hemoglobin (Hb), hematocrit
(Hct), and red blood cells (RBC) was revealed in EPO
groups at 12 months (Hb, group A: 10.4 ± 0.6 g/dl base-
line and 12.3 ± 0.6 g/dl 12 months, P \ 0.01; group B:
9 ± 3.4 g/dl baseline, 11.7 ± 0.8 g/dl 12 months P \ 0.01;
control group: 10.6 ± 0.4 g/dl baseline 11.9 ± 0.8 g/dl
12 months P ns; Hct, group A: 30 ± 1.2% baseline,
34.2 ± 2.3% 12 months, P \ 0.001; group B: 30.8 ±
1.3% baseline, 34 ± 2% 12 months, P \ 0,00001; control
group 32 ± 1.7% baseline and 34 ± 2% at 12 months, P
ns; RBC, group A 3.6 ± 0.7 mil/mm3 baseline, 3.90 ± 2
mil/mm3 12 months P \ 0.00001; group B: 3.2 ± 0.2
mil/mm3 baseline, 3.8 ± 0.2 mil/mm3 12 months,
P \ 0.00001; control group: 3.2 ± 0.2 mil/mm3 baseline
vs. 3.8 ± 0.2 mil/mm3 at 12 months, P ns). Significant
increases in CrCl were revealed in the study population
neither after 12 months of treatment nor between EPO
groups with respect to control group. Plasma BNP levels in
EPO groups were significantly reduced after 12 months
(group A: 512 ± 127 pg/ml baseline vs. 335 ± 138 pg/ml
12 months P \ 0.01; group B: 659 ± 321 pg/ml baseline
vs. 449 ± 274 pg/ml 12 months P \ 0.01). No significant
difference was found for BNP plasma levels after
12 months in control group (610 ± 231 baseline vs.
582 ± 209 pg/ml, P ns) with a significant difference
between EPO groups and control groups after12 months of
treatment (405 ± 235 pg/ml vs. 582 ± 209 pg/ml P \ 0.01).
(Table 2). NYHA class was significantly reduced in EPO
groups after 12 months of follow-up (group A: 3.38 ± 0.5
baseline vs. 2.7 ± 0.7 12 months, P \ 0.05; group B:
3.5 ± 0.5 baseline vs. 2.78 ± 0.8 12 months, P \ 0.01;
control group: 3.32 ± 0.47 baseline vs. 3.2 ± 0.6, P ns;
P intergroups \0.01) and showed a significant inverse
correlation with Hb levels (r = -0.45; P \ 0.05, Fig. 1).
Finally, an inverse correlation was observed between BNP
and Hb levels in EPO groups (r = -0.70, P \ 0.001;
Fig. 2a, b).
Secondary end points
Four patients died during the year study: 3 in control group
(1 for sudden death, 2 for refractory CHF) and 1 in EPO
groups (from sudden death). After 12 months of treatment,
hospitalization rate was significantly reduced in EPO
groups with respect to control group (25% vs. 56%
P \ 0.05, Fig. 3). No significant change in blood pressure,
body weight, and myocardial events were seen.
Discussion
Small clinical trials have shown that the correction of ane-
mia with erythropoietin or its derivatives with oral or
intravenous iron treatment has been associated with lower
hospitalization rates, better quality of life, improved exer-
cise tolerance, and reduced neuro-hormonal activation and
pro-inflammatory cytokine expression [11–19]. Despite
these reports, the only large multicenter randomized placebo
controlled interventional trial was not able to demonstrate
significant clinical benefits with darbepoetin alfa therapy, a
long-acting erythropoiesis stimulating agent (ESA) [20]. In
the current study, we found the increase in Hb, RBC, and
HCT values lead to NYHA class reduction and BNP level
decreases. In this paper, we extend previous published data
showing that EPO treatment in patients with CRS anemia
leads to reverse ventricular remodeling together with sys-
tolic function improvement [18]. All these changes were
supported by the fall in BNP that we found in the treated
patients: since BNP is one of the most powerful markers of
adverse outcomes in CHF, its plasma lowering might indi-
rectly signal an improvement in cardiac function and out-
come in patients with CRS in whom the anemia is corrected
[23]. Secondary end points also demonstrated significantly
reduced hospitalization without any modification in body
weight, blood pressure, or other potential adverse effects.
Our results appear in contrast with respect to recent clinical
trials showing negative or neutral effects of EPO adminis-
tration in patients with chronic kidney diseases (CKD).
However, we need to keep in mind that patients enrolled in
the cited studies are quite different: only 23 and 31% had a
Table 1 Clinical and
laboratory characteristics in the
treated group (A and B) and
control group
NYHA class Group A 13 pz Group B 14 pz Control group 25 pz
8 III/5 IV 7 III/7 IV 15 III/10 IV
Coronary artery disease 6 8 12
Hypertension 7 11 15
Body mass index (g/cm2) 27.9 ± 6 28.1 ± 1 26.5 ± 3
LVEF (%) 28.3 ± 4.3 31.2 ± 8.4 30.9 ± 5.9
Hb concentration (g/dl) 10.4 ± 0.6 9 ± 3.4 9.3 ± 3.4
Creatinine clearance (ml/min) 45.8 ± 5.9 44.2 ± 6.2 44.8 ± 5.2
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CKD history. Therefore, Hb target was higher with respect
to our study [24–26]. Patients with anemic HF are often
affected by primary iron deficiency, for this reasons, all the
group included in our study were submitted to oral iron
therapy. Recently, Anand et al. demonstrated the pivotal
role of iron administration in this context [27].
The effects we saw may be related not only to the EPO-
induced correction of anemia and the decrease in volume
overloading but also to EPO’s cytoprotective properties that
lead to a significant increase in cardiac contractile reserve.
Recently, an experimental study showed prevention of car-
diac remodeling by low doses of EPO treatment independent
of hematocrit increase [28]. This is in keeping with other
animal studies demonstrating that EPO appears able to
directly improve LV function even without increasing the
hemoglobin [29, 30]. EPO can induce myocardial neovas-
cularization and prevent myocardial cell apoptosis, myo-
cardial fibrosis, and oxidative stress in animal models
secondary to myocardial infarction, CHF or ischemic injury.
Study limitations
This single-center study was limited by its small sample
size. The investigators were blinded to the EPO medica-
tion. Many of the parameters evaluated during follow-up
that improved with treatment were objective and could not
be easily biased by the investigator. It is likely that the
baseline weight of some subjects was above their ideal
weight due to fluid retention upon hospital admission. We
did not measure all iron parameters and particularlyT
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transferrin saturation, even if all patients took oral ferrous
gluconate.
Conclusions
Correction of anemia in patients with CRS leads to an
improvement in NYHA class with hospitalization rate
reduction. All these positive changes occur together with
BNP decrease and appear related to anemic status correction.
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